GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Novo Nordisk A/S has finalized a groundbreaking deal to address the rising demand for its weight-loss drug, Wegovy, and diabetes treatment, Ozempic. In a significant move, Novo's largest shareholder has acquired Catalent Inc., one of the world's leading drug-manufacturing companies, for a staggering $16.5 billion, including debt.
As per Reuters, this three-way arrangement will see the Danish pharmaceutical company pay $11 billion to obtain three of Catalent's manufacturing facilities, fortifying its supply chain and overcoming recent shortages of Wegovy and Ozempic.
Fierce Competition and the Emergence of Zepbound
Novo Nordisk races to enhance its supply chain but faces fierce competition from Eli Lilly & Co. Lilly's obesity shot, Zepbound, was recently approved and is expected to become the highest-selling drug in history.
Yahoo pointed out that patient trials have demonstrated greater weight loss results with Lilly's drug compared to anything Novo has developed thus far. With this in mind, Novo's strategic acquisition of Catalent aims to solidify its market position and fend off the intensifying rivalry.
Novo Nordisk's purchase of Catalent has garnered support from Elliott Investment Management, an activist investor with a stake in the US company. The agreement values Catalent at $63.50 per share in cash, reflecting a 17% premium to its Friday closing price. However, Catalent faced manufacturing issues in September 2021, affecting its production of COVID-19 vaccines for Moderna Inc. and one of Regeneron Inc.'s top-selling drugs.
Novo Nordisk's Strategic Move to Meet Surging Demand Boosts its Market Value
Shares of Novo Nordisk have been surging alongside the increasing demand for its obesity and diabetes drugs, reaching a record high. With a market value exceeding $520 billion, Novo is now Europe's largest publicly traded company. Meanwhile, Catalent's stock rose by up to 10% in New York as news of the deal emerged.
This monumental $16.5 billion agreement between Novo Nordisk and Catalent marks the largest deal ever for companies and their controlling shareholder, Novo Holdings A/S. Novo Holdings currently controls 77% of the voting rights in the Danish drugmaker, further solidifying its influence and position in the pharmaceutical industry.
Photo: Novo Nordisk Newsroom
